🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 28/04/2014 | 64,64 | 66,10 | 62,42 | 64,51 | +0,50% | 5,69% | 1.333.500 |
| 25/04/2014 | 65,55 | 66,32 | 64,02 | 64,19 | -3,01% | 3,51% | 1.120.400 |
| 24/04/2014 | 66,96 | 67,49 | 64,05 | 66,18 | -1,11% | 5,14% | 1.204.700 |
| 23/04/2014 | 69,49 | 69,49 | 66,17 | 66,92 | -2,02% | 4,78% | 1.445.200 |
| 22/04/2014 | 65,69 | 69,05 | 65,67 | 68,30 | +4,32% | 5,15% | 1.862.200 |
| 21/04/2014 | 64,52 | 65,56 | 63,04 | 65,47 | +2,03% | 3,91% | 1.103.800 |
| 17/04/2014 | 64,18 | 65,68 | 63,42 | 64,17 | -0,34% | 3,52% | 1.387.400 |
| 16/04/2014 | 63,81 | 64,82 | 62,83 | 64,39 | +1,80% | 3,12% | 1.459.500 |
| 15/04/2014 | 62,83 | 63,97 | 59,79 | 63,25 | +1,30% | 6,65% | 1.886.000 |
| 14/04/2014 | 64,05 | 65,14 | 61,19 | 62,44 | -0,98% | 6,17% | 1.695.800 |
| 11/04/2014 | 64,97 | 67,64 | 63,00 | 63,06 | -4,00% | 7,14% | 2.139.900 |
| 10/04/2014 | 69,32 | 69,81 | 65,31 | 65,69 | -6,09% | 6,49% | 2.545.700 |
| 09/04/2014 | 65,59 | 70,06 | 65,32 | 69,95 | +7,04% | 7,23% | 2.107.100 |
| 08/04/2014 | 65,84 | 67,00 | 64,60 | 65,35 | -1,58% | 3,65% | 1.677.400 |
| 07/04/2014 | 66,00 | 67,24 | 64,05 | 66,40 | +0,85% | 4,83% | 1.646.400 |
| 04/04/2014 | 70,06 | 70,15 | 65,44 | 65,84 | -4,75% | 6,72% | 2.207.100 |
| 03/04/2014 | 71,96 | 72,74 | 67,93 | 69,12 | -4,40% | 6,68% | 1.720.700 |
| 02/04/2014 | 72,00 | 73,10 | 71,65 | 72,30 | +0,60% | 2,01% | 1.316.700 |
| 01/04/2014 | 71,32 | 73,12 | 70,76 | 71,87 | +1,63% | 3,31% | 2.319.500 |
| 31/03/2014 | 68,17 | 71,35 | 68,01 | 70,72 | +4,31% | 4,90% | 1.860.600 |
| 28/03/2014 | 71,07 | 72,67 | 67,49 | 67,80 | -4,21% | 7,29% | 1.425.600 |
| 27/03/2014 | 70,30 | 71,65 | 68,24 | 70,78 | +0,48% | 4,85% | 1.786.200 |
| 26/03/2014 | 72,56 | 72,77 | 69,86 | 70,44 | -2,03% | 4,01% | 1.656.900 |
| 25/03/2014 | 72,75 | 73,92 | 70,31 | 71,90 | -0,75% | 4,96% | 1.409.800 |
| 24/03/2014 | 74,30 | 74,60 | 70,58 | 72,44 | -1,88% | 5,41% | 1.982.600 |
| 21/03/2014 | 77,50 | 77,75 | 72,82 | 73,83 | -5,07% | 6,36% | 3.525.900 |
| 20/03/2014 | 77,72 | 78,57 | 76,60 | 77,77 | -0,04% | 2,53% | 957.300 |
| 19/03/2014 | 78,73 | 79,20 | 77,16 | 77,80 | -1,52% | 2,59% | 1.361.800 |
| 18/03/2014 | 78,00 | 79,95 | 77,69 | 79,00 | +1,67% | 2,90% | 959.600 |
| 17/03/2014 | 77,50 | 79,51 | 77,02 | 77,70 | -0,79% | 3,21% | 1.301.600 |